Hong Kong registry for diabetes-related fatty liver disease
Official title: The Establishment of Hong Kong Diabetes Steatotic Liver Disease Register
Run by Chinese University of Hong Kong · NCT07437157 · Data updated 2026-11-12
This project will see how common and how severe fatty liver is among adults with type 2 diabetes in Hong Kong.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 1000 (estimated) |
| Sponsor | Chinese University of Hong Kong Academic / other |
| Locations | 1 site (Hong Kong, New Territories) |
| Status | Recruiting |
| Started | June 11, 2025 |
| Main results expected | February 28, 2026 |
| Study ends | February 28, 2027 |
| Registry record updated | February 27, 2026 |
| Trial ID | NCT07437157 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18 or older with type 2 diabetes who can give written informed consent are the intended participants.
✕Probably not a fit
People with type 1 diabetes, those with terminal illness, or anyone judged ineligible by the investigators are not candidates and may not benefit from this registry.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational registry enrolls adults with type 2 diabetes at the Chinese University of Hong Kong / Prince of Wales Hospital to systematically record liver health and metabolic data. Participants will undergo noninvasive liver tests such as controlled attenuation parameter (CAP) and liver stiffness measurement (LSM), alongside routine blood tests and clinical history. The registry is designed to quantify the prevalence and severity of metabolic dysfunction-associated steatotic liver disease (MASLD) in people with T2DM and to identify clinical factors linked with advanced fibrosis. No experimental treatments are given; the data will support epidemiologic analyses and guide future clinical research.
Why it matters
Potential benefit: If successful, the registry could help identify people with diabetes who have undiagnosed fatty liver or advanced fibrosis so they can receive earlier monitoring or treatment.
How similar studies have gone: Previous observational studies and registries have reported high rates of hepatic steatosis and some advanced fibrosis in people with T2DM, supporting the value of this data-collection approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * T2DM. * Aged ≥ 18 years. * Able and willing to give Informed written consent. Exclusion Criteria: * Type 1 diabetes. * Terminal illness such as malignancy with limited life expectancy. * Any condition, as judged by the investigators, as ineligible to participate in this study.
Where it's running
-
Department of Medicine and Therapeutics, The Chinese University of Hong Kong (CUHK), Ward 3M, Diabetes and Endocrine Research Centre, 3/F Day Treatment Block and Children Wards (Old Block), Prince of Wales Hospital
Hong Kong, New Territories, Hong Kong Recruiting
Study contacts
- Study coordinator: Alice Pik Shan Kong, MD
- Email: alicekong@cuhk.edu.hk
- Phone: +852 3505 2648
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Health profile of MASLD in Kazakhstan and real-world use of Ursosan in Almaty
This study tests how MASLD appears in adults in Kazakhstan and how Ursosan is used in real-world care for a subgroup in Almaty.
-
Endohepatology-based reclassification of treatment indication in high-risk MASLD
This study tests whether an endohepatology assessment can change treatment decisions for adults with high-risk MASLD.
-
ALN-CIDEB in adults with MASLD to see if it helps the liver
This study tests whether ALN-CIDEB can help adults with MASLD and its liver damage compared to placebo.
-
Pancreatin Added to Standard Diabetes Therapy
Researchers are testing whether adding pancreatin helps people with type 2 diabetes see better blood sugar control when they already take oral meds or insulin.
-
Liver Fat and Scarring in People Suspected of Non-Celiac Wheat Sensitivity
This study looks to see if people with non-celiac wheat sensitivity have liver fat or fibrosis and how this relates to IBS/FD and celiac disease.
-
BGM0504 vs. semaglutide in Chinese adults with obesity-related T2DM
In Chinese adults with type 2 diabetes and obesity who aren’t well controlled by diet and exercise, this trial tests BGM0504 injections once a week for 52 weeks against semaglutide to see which helps more with blood sugar, weight, and safety, including whether diabetes stays in remission after stopping treatment.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.